Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
Crossref DOI link: https://doi.org/10.1186/s12933-016-0355-z
Published Online: 2016-02-24
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ferdinand, Keith C.
Botros, Fady T.
Atisso, Charles M.
Sager, Philip T.
Funding for this research was provided by:
Eli Lilly and Company (US)